Literature DB >> 19327226

Evaluation of the efficacy of an educational program for rheumatoid arthritis patients.

B E Lovisi Neto1, F Jennings, C Barros Ohashi, P G Silva, J Natour.   

Abstract

OBJECTIVE: To evaluate the efficacy of an educational program for patients with rheumatoid arthritis in relation to their knowledge about the disease and to their psychosocial and physical health status.
MATERIALS AND METHODS: The study included patients with rheumatoid arthritis classified according to the American College of Rheumatology criteria without any previous participation in disease-specific educational programs. The patients were randomly assigned to an educational program intervention or a waiting list. The intervention was a 6-week educational program consisting of weekly sessions lasting 1 hour each. Evaluations by a blind assessor were made prior to intervention and after 45, 90 and 180 days. The main outcome variables were the Patient Knowledge Questionnaire and the Short-form Health Survey (SF-36) quality of life questionnaire. Secondary outcome variables were the Health Assessment Questionnaire, Visual Analogue Pain Scale, Beck Depression Inventory and State-Trait Anxiety Inventory.
RESULTS: Patients in the intervention group (n=28) had significant improvement in disease-specific knowledge compared to patients in control group (n=30). There was no significant difference between the groups in terms of pain, depression, anxiety or functional capacity, but the "general health perception" subscale of SF-36 showed a significant improvement in the intervention group (p=0.041). There was a positive correlation between improvement of disease-specific knowledge and schooling.
CONCLUSION: Patients who attended the educational program had significant improvement in disease-specific knowledge and general health perception. No harmful effects on their psychosocial status were noticed. The acquisition of knowledge was also found to be proportional to schooling.

Entities:  

Mesh:

Year:  2009        PMID: 19327226

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Compliance with treatment of rheumatoid arthritis.

Authors:  Raili Müller; Riina Kallikorm; Kaja Põlluste; Margus Lember
Journal:  Rheumatol Int       Date:  2011-09-24       Impact factor: 2.631

2.  Identifying real and perceived barriers to therapeutic education programs for individuals with inflammatory arthritis.

Authors:  Lorna Bain; Ruheena Sangrar; Carolyn Bornstein; Sara Lukmanji; Sandani Hapuhennedige; Carter Thorne; Karen A Beattie
Journal:  Clin Rheumatol       Date:  2015-10-29       Impact factor: 2.980

3.  [EULAR recommendations for patient education of people with inflammatory arthritis. Translation and evaluation in Germany].

Authors:  J Patermann; I Ehlebracht-König; G Lind-Albrecht; E Genth; A Reusch; R Küffner; U Müller-Ladner; J Braun
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

4.  Patient experiences, attitudes and expectations towards receiving information about anti-TNF medication: a quantitative study.

Authors:  Jon Packham; Paul Arkell; Tom Sheeran; Ann Brownfield; Anthony Cadwgan; Sarah Ryan
Journal:  Clin Rheumatol       Date:  2017-05-19       Impact factor: 2.980

5.  The Effects of Patient Education on Psychological Status and Clinical Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.

Authors:  Zugui Wu; Yue Zhu; Yi Wang; Rui Zhou; Xiangling Ye; Zehua Chen; Congcong Li; Junyi Li; Zixuan Ye; Zhenbang Wang; Wengang Liu; Xuemeng Xu
Journal:  Front Psychiatry       Date:  2022-03-17       Impact factor: 4.157

6.  Unmet Information Needs of Patients with Rheumatic Diseases: Results of a Cross-Sectional Online Survey Study in Germany.

Authors:  Christian Becker; Matthias Diener; Axel J Hueber; Jörg Henes; Martin Krusche; Yuriy Ignatyev; Susann May; Ulrike Erstling; Corinna Elling-Audersch; Johannes Knitza; Felix Muehlensiepen
Journal:  Int J Environ Res Public Health       Date:  2022-06-09       Impact factor: 4.614

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.